Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

证券代码：003020 证券简称：立方制药 公告编号：2025-067 合肥立方制药股份有限公司 关于完成董事会换届选举及聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开 2025 年第一次临时股东大会，选举产生了公司第六届董事会 4 名非独立董事、3 名独立董事，与公司于 2025 年 8 月 29 日召开的职工代表大会选举产生的 1 名职 工代表董事，共同组成了公司第六届董事会。同日，公司召开第六届董事会第一 次会议，选举产生了董事长、副董事长、董事会专门委员会委员，并聘任新一届 高级管理人员。现将具体情况公告如下： 一、第六届董事会组成情况 （一）董事会组成 战略委员会：季俊虬先生（主任委员）、杨模荣先生、李进华先生； 审计委员会：杨模荣先生（主任委员）、史静先生、方芸女士； 1 提名委员会：李进华先生（主任委员）、史静先生、崔欢喜先生； 公司第六届董事会由 8 名董事组成，其中非独立董事 5 名（含职工代表董事 1 名），独立董事 3 名，具体如下 ...

1、本次股东大会未出现否决提案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 证券代码：003020 证券简称：立方制药 公告编号：2025-065 合肥立方制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、召开时间 （1）现场会议时间：2025 年 8 月 29 日（星期五）下午 14:30。 （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为：2025 年 8 月 29 日 9:15—9:25、9:30—11:30、13:00—15:00；通过深圳证券交易所互联 网投票系统投票的时间为：2025 年 8 月 29 日 9:15-15:00。 2、现场会议召开地点：安徽省合肥市文曲路 446 号科研综合楼五楼会议中 心。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：公司董事长季俊虬先生。 6、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规、规范性文件和《公司章程》 ...

合肥立方制药股份有限公司 证券代码：003020 证券简称：立方制药 公告编号：2025-066 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 同意选举季俊虬先生为公司第六届董事会董事长，任期三年，自本次董事会 决议通过之日起生效。 表决情况：同意 8 票，反对 0 票，弃权 0 票。 1 合肥立方制药股份有限公司（以下简称"公司"）第六届董事会第一次会议 于公司 2025 年第一次临时股东大会、公司职工代表大会选举产生第六届董事会 成员后召开，经全体董事同意豁免本次会议通知期限要求，以口头方式向全体董 事发出会议通知。会议于 2025 年 8 月 29 日下午 16:00 在科研综合楼五楼会议中 心以现场表决的方式召开，会议应出席董事 8 人，实际出席董事 8 人。公司高级 管理人员候选人列席了会议。会议由全体董事共同推举季俊虬先生主持。 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》《董事会议事规则》的规定。 二、董事会会议审议情况 与会董事经过认真审议并投票表决，审议通过了如下议案： 1 ...

Group 1 - The company held its first extraordinary general meeting of shareholders on August 29, 2025, at 14:30 in Hefei, Anhui Province [1][2] - The meeting was convened following the resolution of the company's fifth board of directors on August 12, 2025, and the notice was published on August 13, 2025 [2][3] - A total of 6 proposals were reviewed during the meeting, including amendments to the company's articles of association and the election of the sixth board of directors [3][4] Group 2 - 17 shareholder representatives attended the meeting in person, representing 18 shareholders, while 123 shareholders participated via online voting, accounting for 4.9058% of the total voting shares [3][4] - The meeting's convenor was the company's board of directors, which met the qualifications set by Chinese laws and the company's articles of association [5] Group 3 - The voting process included both on-site and online voting, with results announced at the meeting [6][7] - The first proposal regarding the amendment of the articles of association was passed with 99.9904% approval from the attending shareholders [6][10] - The election of non-independent directors and independent directors also received significant support, with approval rates around 98.1595% [7][9] Group 4 - The proposal for the three-year dividend return plan (2026-2028) was approved with 99.9638% of the votes [12][13] - The adjustment of independent director allowances was also passed with a similar majority [13]

证券代码：003020 证券简称：立方制药 公告编号：2025-065 合肥立方制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （1）现场会议时间：2025 年 8 月 29 日（星期五）下午 14:30。 其中：通过现场投票的股东及股东代理人 17 名（代表 18 名股东），代表股 份 108,670,270 股，占公司有表决权股份总数的 57.1401%。通过网络投票的股东 （2）中小股东出席会议情况 通过现场和网络投票的中小股东及代理人 129 名，代表股份 12,107,053 股， 占公司有表决权股份总数的 6.3660%。 其中：通过现场投票的中小股东及代理人 6 名，代表股份 2,777,149 股，占 公司有表决权股份总数的 1.4603%。 （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为：2025 年 8 月 29 日 9:15—9:25、9:30—11:30、13:00—15:00；通过深圳证券交易所互联 网投票系统投票的时间为：2025 年 8 月 29 日 9:15-15 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于合肥立方制药股份有限公司 2025年第一次临时股东大会的法律意见书 致：合肥立方制药股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受合肥立方制药股份有限 公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 8 月 29 日下 午14时30分在安徽省合肥市文曲路446号科研综合楼五楼会议中心召开的2025 年第一次临时股东大会（以下称"本次股东大会"），并依据《中华人民共和国公 司法》等中国法律、法规和相关规范性文件（以下称"中国法律法规"）及《合肥 立方制药股份有限公司章程》（以下称"公司章程"）的规定，就本次股东大会的 召集和召开程序、出席会议人员资格、召集人资格、会议表决程序和表决结果等 事宜（以下称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件， 包括但不限于公司第五届董事会第二十二次会议决议以及根据上述决议内容刊 登的公告、本次股东大会的 ...

Group 1 - The A-share chemical pharmaceutical sector experienced a rebound, with notable stock performances [1] - Sunflower stock surged by 20% and hit the daily limit, indicating strong market interest [1] - Other companies such as Duoyi Pharmaceutical and Huahai Pharmaceutical saw increases of over 13% and 9% respectively, reflecting a positive trend in the sector [1]

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Core Insights - The report highlights the rapid development of the AI industry in China, driven by the government's "Artificial Intelligence+" initiative, which sets ambitious goals for AI integration across various sectors by 2035 [5] - The chemical raw materials sector is experiencing growth due to increased demand for AI servers, with a focus on high-frequency and high-speed copper-clad laminate materials [6] - The pharmaceutical company Lifan Pharmaceutical is set to launch a new ADHD treatment, with significant increases in R&D investment [7] - Runfeng Co. has reported substantial growth in operating performance, driven by global operations [8] - Times New Materials has seen a rise in revenue and profit, with new materials becoming a key growth area [12] - Guangqi Technology is experiencing rapid growth in its metamaterials business, with steady progress in production base construction [15] - Changrun Co. has improved profit margins significantly, driven by product diversification and strong overseas contributions [17] - Longcheng Securities has shown comprehensive improvement in performance, with investment business driving growth [24] - Baofeng Energy's projects in Inner Mongolia are contributing to revenue growth, with ongoing projects being actively advanced [28] Industry Commentary - The "Artificial Intelligence+" policy aims for deep integration of AI in six key areas by 2027, with a target of over 90% application penetration by 2030 [5] - The new materials sector is benefiting from the rising demand for AI servers, with the global AI server market projected to grow significantly [6] - The pharmaceutical industry is seeing innovation with new drug approvals and increased R&D spending, particularly in ADHD treatments [7] - The agricultural chemicals market is recovering, with a focus on high-margin products and global market expansion [10] - The wind power sector is expected to maintain high growth, driven by new installations and international collaborations [12] - The metamaterials market is expanding, with increasing demand for advanced materials in various applications [15] - The automotive parts industry is adapting to market changes, with a focus on product diversification and international production capabilities [17] Company-Specific Insights - Lifan Pharmaceutical's revenue for H1 2025 was 732 million yuan, with a net profit of 90.23 million yuan, reflecting a 16.53% increase [7] - Runfeng Co. anticipates revenues of 1.796 billion yuan in 2025, with net profits projected to reach 198 million yuan [9] - Times New Materials reported H1 revenue of 9.256 billion yuan, with a net profit of 303 million yuan, indicating a 36.66% increase [12] - Guangqi Technology's H1 revenue was 943 million yuan, with a net profit of 386 million yuan, showing a 6.75% increase [15] - Changrun Co. achieved H1 revenue of 1.4 billion yuan, with a net profit of 107 million yuan, despite a slight decline in revenue [17] - Longcheng Securities reported H1 revenue of 2.859 billion yuan, with a net profit of 1.385 billion yuan, reflecting a 91.92% increase [26] - Baofeng Energy's H1 revenue reached 22.82 billion yuan, with a 35% year-on-year increase [28]